SecBot SecBot
6-K ·Filed May 18, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001178913-26-002750
Notable filing: 6-K
Actionable Insight • Neutral

Flat quarter with no financial surprises and pipeline milestones reaffirmed. Traders should watch for the MAIA-ovarian interim analysis by Q1 2027 and any rilvegostomig data readouts at ASCO 2026 as the next potential inflection points. No immediate trading trigger from this filing.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.86
T+0 close · May 18, 2026 · via day close
Latest settled
−12.59%
T+60 · $2.50
Vs SPY
−17.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $2.86entry
  2. T+1 · 6mo ago −4.55%α −3.90% · $2.73
  3. T+5 · 6mo ago −7.34%α −8.96% · $2.65
  4. T+20 · 5mo ago −29.02%α −30.60% · $2.03
  5. T+60 · 3mo ago −12.59%α −17.44% · $2.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1 2025) and net loss of $7.7M ($0.08/share) vs $7.2M ($0.08/share) in the prior year. Cash and equivalents stood at $134.9M with runway into 2029. Clinical milestones remain on schedule: COM701 MAIA-ovarian interim analysis by Q1 2027, AstraZeneca advancing rilvegostomig across 11 Phase 3 trials, and Gilead-partnered GS-0321 Phase 1 progressing. The filing is a routine quarterly update with no-surprise update with no material financial deviation from the prior period.

Key Facts

  • Q1 2026 revenue $2.2M vs $2.3M in Q1 2025, essentially flat with a slight decline
  • Net loss $7.7M ($0.08/shr) vs $7.2M ($0.08/shr) in Q1 2025, slightly wider loss, EPS unchanged
  • Cash, equivalents, short-term deposits, and marketable securities of $134.9M as of March 31, 2026
  • Cash runway expected to fund operations into 2029 with no debt
  • R&D expenses increased to $6.9M from $5.8M YoY driven by clinical costs for MAIA-ovarian trial
  • COM701 MAIA-ovarian trial actively enrolling; interim PFS analysis on track by Q1 2027
  • AstraZeneca advancing rilvegostomig in 11 ongoing Phase 3 trials; new data to be released at ASCO 2026
  • Gilead-partnered GS-0321 Phase 1 trial progressing as planned
  • as per plan

Financial Impact

Revenue essentially flat (-4.7.8% QoQ from the $1.1M prior?), but compared to prior year $2.3M revenue is ~$0.1M lower. Net loss widened by $0.5M. Cash burn of ~$7.7M per quarter implies ~2.7 years of runway. No debt. No material deviation from prior disclosed pipeline milestones.

revenuenet losscash positionR&D expenses

Risk Factors

  • Revenue remains de minimis and dependent on milestone-based from Gilead &&dependent on partner milestones, no core product revenue yet )
  • Operating loss widening from higher R&D spend without commensurate revenue growth
  • Clinical trial risks: MAIA-ovarian may fail interim analysis; partner programs could be deprioritized

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-002750
Document: zk2635352.htm0001178913-26-002750
Document: 0001178913-26-002750-index-headers.html0001178913-26-002750
Document: 0001178913-26-002750-index.html0001178913-26-002750
Document: 0001178913-26-002750.txt0001178913-26-002750

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026